For example, ALT-801, a biologic drug composed of interleukin-2 (IL-2) genetically fused to a soluble humanized TCR specific to a p53-derived antigen, is currently in phase II clinical trials in combination with gemcitabine (bladder cancer) and cisplatin (metastatic melanoma) (37, 38). The gene discussed is IL2; the disease is urinary bladder cancer.